Bioheng is a biotechnology company established in 2017, specializing in the development and commercialization of universal type CAR-T (UCAR-T) cell therapy products. With a team of doctors and experienced industry professionals, the company has grown to become a research and industrialization team of over 150 researchers. In 2021, Bioheng secured a funding round of 5.

2 billion yuan from prominent investors such as Gao Diaochuang and Desheng Capital. The company has successfully developed universal CAR-T cell therapy products and collaborated with several renowned hospitals for early-stage clinical trials. They have also obtained patents for CAR-T preparation and recognition as an orphan drug.

Bioheng is currently operating clinical transformation centers, GMP production workshops, and plans to build a commercial production facility for cell therapy with the capacity to meet the treatment needs of 19,000 cancer patients annually. Their commitment to innovation and collaboration has positioned Bioheng as a leading enterprise in the field of biomedicine